Should I participate in MS Trial Or Not? BG112 Oral Meds

Hi all!
My neuroligist has givein me the option of partaking in the trial outlined below. Im 24 n was told i had MS about 4years ago after i got blurred vision (optic neurities), i was takeing beta-interferon for about 3 years and he advised me that i could take a break for awhile around 6months ago as i was starting to have some discomfort wit injection sites. iv been off it now for 6 months and so am an ideal candidate for these trials (nothing in the system). The problem is that im starting to feel like he only told me to take this break so i could go ahead with the trial. im pure confused as to if i should do it or not. cant find any info on this BG112, all i know is that it is in tablet form which sounds fantastic to me! the copaxone is an injection which wouldnt be the end of the world as i wouldnt be any better or worse off than i was 6 months ago! if anyone can give me any info/advice id really appreciate it! (The neuroligists e-mail to me is below)
Thanks,

John
------------------------------------------ ------


John
The trial is of an agent called BG112 (it hasn't got a 'real' name yet) which is an oral medication that is being tested in MS. The early studies (Phases I and II) have already been done showing promise for this drug and the study we hope to be involved with is the Phase III - the last hurdle before the drug is approved for usage. It is a randomised controlled trial. This means that any volunteer or their doctor cannot choose the treatment they receive. If they agree to go into the study they can be 'randomised' to receive either the new treatment or the older treatment to which it is being compared. If that process is not randomised the results may not be accepted by the scientific world as that would have introduced a 'bias' into the results. The advantages of taking part in a trial are that you might receive the new treatment and that you are monitored very closely - usually every 6-8 weeks throughout the trial and afterwards. You are also helping to test this new treatment for other people. The disadvantage is that you must accept the randomisation at the start of the trial which means you might get the new treatment or the treatment it is being compared to. Sometimes the comparison is a placebo, i.e. no treatment at all just a 'coloured pill'. In this trial the comparison is between BG112 and the older, already established treatment of Copaxone which is already shown to be of benefit. If the person's condition deteriorates at any time during the trial the patient and the doctor are entitled to withdraw from the study and go ahead with whatever approved tried and tested treatment is available.